Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates

Company Performance - Bausch Health reported quarterly earnings of $1.12 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, and showing an increase from $1.03 per share a year ago, representing an earnings surprise of 8.74% [1] - The company posted revenues of $2.51 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.33%, compared to revenues of $2.24 billion in the same quarter last year [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is $1.12 on revenues of $2.52 billion, and for the current fiscal year, it is $3.60 on revenues of $9.51 billion [7] - The estimate revisions trend for Bausch is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]